Ocular Therapeutix, Inc. (Nasdaq: OCUL) 39.7% HIGHER; announced the Phase 3 clinical development strategy for its OTX-TP (sustained release travoprost) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE